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Abstract
Background and Purpose—Erythropoietin (EPO) has received growing attention because of
its neuro-regenerative properties. Preclinical and clinical evidence supports its therapeutic
potential in brain conditions like stroke, multiple sclerosis and schizophrenia. Also in Friedreich
ataxia, clinical improvement after EPO therapy was shown. The aim of the present study was to
assess possible therapy-associated brain white-matter changes in these patients.
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Methods—Nine patients with Friedreich ataxia underwent Diffusion Tensor Imaging (DTI)
before and after EPO treatment. Tract-based spatial statistics (TBSS) was used for longitudinal
comparison.
Results—We detected widespread longitudinal increase in fractional anisotropy (FA) and axial
diffusivity (D||) in cerebral hemispheres bilaterally (p<0.05, corrected), while no changes were
observed within the cerebellum, medulla oblongata and pons.
Conclusions—To the best of our knowledge, this is the first DTI study to investigate the effects
of erythropoietin in a neurodegenerative disease. Anatomically, the diffusivity changes appear
disease-unspecific, and their biological underpinnings deserve further study.
INTRODUCTION
EPO has received considerable attention because of its neuroprotective properties,1, 2 and
there is evidence from animal studies pointing to a neuroregenerative potential.3–6
Friedreich ataxia (FRDA) is the most common inherited ataxia in those of Western
European descent, and is caused by an intronic GAA triplet repeat expansion in the Frataxin
gene (FXN; OMIM606829) on chromosome 9q13.7, 8. Larger GAA expansions are
associated with earlier age of onset and greater clinical severity.9 Frataxin is a small
mitochondrial protein involved in iron metabolism, and its deficiency leads to mitochondrial
dysfunction and oxidative stress.8 Expression varies between tissues. In FRDA, the primary
sensory neurons are specifically affected, which results in atrophy of the spinal cord’s dorsal
column and spinocerebellar tracts, which carry the proprioceptive information for the
cerebellum.10
Magnetic resonance imaging (MRI) in FRDA has revealed volume loss in the spinal cord,
brainstem, cerebellum and optic chiasm.11–14 DTI has shown white matter (WM) changes
including decreased FA and/or higher Mean Diffusivity (MD). These changes were present
in the brainstem and cerebellum, but also in supratentorial regions like the optic
radiation.15–17 Diffusivity indices also correlated with number of triplet repeats, duration of
illness and scores of clinical severity.16, 17
There is evidence that EPO could be an effective treatment in FRDA: Sturm et al. found that
recombinant human EPO (rhuEPO) increases Frataxin levels in isolated lymphocytes from
FRDA patients in vitro.18 Subsequently, significant increase in Frataxin levels and clinical
improvement in FRDA patients treated with rhuEPO were shown.19, 20
Given that DTI indices are a widely used marker of brain WM integrity, and there is
evidence for their validity in FRDA,16, 17 we used DTI in the present study to test for
possible diffusivity changes in FRDA patients after treatment with rhuEPO.
METHODS
Twelve patients with an established diagnosis of FRDA were included in the original
clinical study.19 Demographic and clinical variables are given in Table 1. Exclusion criteria
(described in detail elsewhere19, 20) were all conditions incompatible with EPO treatment,
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particularly hemoglobin levels above 17 mg/dl and a history of thrombosis. All diagnostic
and therapeutic interventions were performed according to the Declaration of Helsinki and
the recommendations of the local Ethics Committee and Security Board after obtaining
written informed consent from the patients.
Study design
In an open-label, Phase II, proof-of-concept study, FRDA patients received 5000IU rhuEPO
subcutaneously three times a week for 2 months. The primary outcome measure was the
serum concentration of Frataxin.19 Thereafter, 10 out of these 12 patients entered a six-
months follow-up study and received 2000 IU rhuEPO three times weekly.20 The rhuEPO
dose reduction was due to reported side effects (transient mental agitation, as well as raised
hemoglobin- and hematocrit-levels). Two patients (see Table 1) chose not to enter the
follow-up study and consequently received rhuEPO only during the initial 2 months. The
primary outcome measures for this follow-up study were two clinical rating scores, the
Friedreich Ataxia Rating Scale (FARS)21 and the Scale for the Assessment and Rating of
Ataxia (SARA).22
Safety was assessed by bi-weekly measurement of hematocrit and hemoglobin, as well as
erythrocyte, reticulocyte and thrombocyte counts.
MRI acquisition
MRI was performed before therapy (baseline) and after 10–12 months (follow-up). All
participants were scanned on the same 1.5 Tesla MRI scanner (Magnetom Vision; Siemens
Medical Solutions, Erlangen, Germany) using a standard circular-polarized head coil. Brain
DTI was acquired in axial orientation using a diffusion-weighted spin-echo single-shot echo-
planar imaging (EPI) sequence with diffusion encoding in 6 directions (TE=94ms,
TR=6000ms, FOV=256, matrix size of 128×128, 35 contiguous axial slices with 3 mm
thickness, b values 0 and 1000s/mm2). MRI scans were evaluated by an experienced
radiologist (K.E.), to rule out structural abnormalities or artifacts. Two patients had to be
excluded because of claustrophobia and another patient due to movement artifacts on MRI.
TBSS
To test for longitudinal diffusivity changes, we performed voxelwise statistical analysis
using TBSS, part of the Oxford Center for Functional MRI of the Brain (FMRIB) Software
Library (FSL).23
First, the diffusion data were corrected for effects of motion and eddy currents through
affine registration to the b0 volume. This was done using FMRIB’s Linear Image
Registration Tool (FLIRT), also part of FSL. Diffusion gradients were rotated accordingly.
After noise-filtering, the images were skull-stripped with the Brain Extraction Tool (BET,
also part of FSL). Next, diffusion tensors were estimated using a weighted least squares
method in Slicer (slicer.org), and FA maps were computed for all subjects.
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Within the TBSS pipeline, all FA images were non-linearly registered to a single subject.
This subject was chosen automatically such that the amount of deformation required for all
the other subjects was minimal.
All FA volumes were then averaged and the resulting mean FA image underwent a thinning
process leading to the extraction of the skeleton, representing the central course of WM
tracts.23 In order to include only voxels clearly located in WM, this skeleton was
thresholded (FA>0.3). This threshold is slightly higher than the default threshold of 0.2, but
is also recommended in the original TBSS publication.23 We chose to use the higher
threshold because it yielded a skeleton more clearly restricted to WM, which should help
avoid partial volume effects.
Each subject’s registered FA data was then projected onto this skeleton. On these data, we
applied a permutation-based voxelwise paired t-test (5000 permutations) in randomise, also
part of FSL.24 The significance threshold was set to p<0.05, family-wise error (FWE)
corrected for multiple comparisons.24
The MD, D||, D⊥ (i.e. radial diffusivity) and b0 images were analyzed using the same
methodology: we applied the nonlinear warps obtained from the FA registrations and the
skeleton projection and performed the same permutation-based test.
In a secondary analysis, we computed Spearman’s correlation coefficient between
longitudinal change in clinical scores (FARS and SARA) and longitudinal change in DTI
parameters, averaged over all significant voxels from the main analysis. This nonparametric
correlation coefficient was used due to the ordinal nature of the clinical scores and the small
sample size.
RESULTS
Comparing scans before and after treatment with rhuEPO, we observed widespread and
bilateral FA increases (p<0.05, FWE corrected), including the frontal, parietal, temporal and
occipital lobes as well as the diencephalon and mesencephalon, but excluding the pons,
cerebellum and medulla oblongata. Increases in D|| were similarly distributed but less
pronounced, largely excluding the temporal and occipital lobes (see Figure 1). These
changes in FA and D|| were attended by unchanged MD, D⊥ and b0 values throughout the
entire brain.
In the correlational analyses, we did not detect correlations between longitudinal DTI
changes and changes in SARA or FARS.
DISCUSSION
To the best of our knowledge, this is the first study showing extensive FA increase in
patients with a neurodegenerative disease, upon administration of a drug aimed to be
neuroregenerative.
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FA, MD, D|| and D⊥ are widely used measures for assessing WM in neurodegenerative
processes. In most cases, these studies have reported decreased FA (often attended by
increased MD and RD), for example in FRDA,15 Huntington’s disease25 and Alzheimer’s
disease.26
In the case of D||, both decreases and increases have been reported in neurodegeneration. In
some of the above-cited studies where FA was reduced, both D|| and D⊥ were found
increased, but with stronger increase of the latter.15, 25–27 In contrast, D|| decline over time
was observed in Huntington’s.28
Even in the case of FA, single studies have reported increases associated with pathological
conditions or reduced functioning, which was primarily interpreted as reflecting reduced
fiber branching or crossing.29
Overall, while we cannot exclude this possibility, it appears unlikely that the longitudinal
FA and D|| increases in our study reflect ongoing neurodegeneration, since these increases
included, for example, the body of the corpus callosum, a highly ordered tract, where no
fiber crossing is expected.
Regarding normal aging, a recent study focusing on the corpus callosum revealed increasing
FA and decreasing MD during childhood and early adolescence, with FA values peaking
from 21 to 29 years.30 As five of the participants in our study were within this particular age
range, we considered the possibility that the increase in FA could be merely due to ongoing
development. This, however, appears unlikely, since FA increase in early adulthood is
combined with prolonged decrease of D||,30 whereas D|| in our patients increased
significantly.
In combined histopathological-imaging studies in animals, axonal and myelin injury were
found to correlate with elevated D|| and reduced D⊥, respectively, 31 and the reverse held
true for regeneration.32 However, there are recent data indicating that the DTI-histology
relationship may be more complex. For example, two recent studies in humans found axonal
density to be correlated with FA and D⊥, but not significantly with D||.33, 34 In the light of
these reports, one can only speculate about the histological basis of the changes seen in our
study, while axonal changes appear as a possible candidate.
Since iron metabolism is affected in FRDA,8 we sought to rule out the possibility that
ongoing iron deposition may have affected the diffusion-weighted data due to signal
changes in the b0 images. However, comparison of these b0 images at baseline and follow-
up did not reveal significant or trend-level alterations. Hence, iron-deposition is unlikely to
explain our findings.
EPO and its derivatives have come into focus as promising candidates for the treatment of
various brain conditions. There has been a wealth of preclinical studies and also some
encouraging clinical trials, particularly in ischemic stroke, multiple sclerosis and
schizophrenia (reviewed in 35).
Egger et al. Page 5
J Neuroimaging. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
EPO and EPO receptors (EPO-R) are expressed in the brain during development and
adulthood.36 As mentioned, several animal studies have demonstrated beneficial effects of
EPO administration after traumatic brain injury or ischemia.3–6
In the context of our DTI findings, it is particularly noteworthy that EPO increased
oligodendrogenesis and reduced WM damage after ischemia in rats.3
Moreover, EPO administered after traumatic brain injury leads to higher glucose levels and
lower lactate levels.37 In FRDA patients, PET studies have shown that glucose metabolism
is initially increased in various brain regions, but decreases again with clinical severity.38
Therefore, the impact of EPO as measured in our study could also be related to an
improvement of energy supply.
Regardless of the exact biological mechanism, we speculate that the changes seen are
reflective of disease-unspecific EPO effects, which is supported by two observations:
Firstly, significant effects were located only in regions that are not primarily affected in
FRDA, i.e. not in the medulla, pons and cerebellum. One could speculate that these regions
have less regenerative potential and are therefore less susceptible to the unspecific
“positive” effects of EPO.
Secondly, we could not detect significant correlations between changes in clinical and
diffusivity parameters, which is likely also related to the small sample size and resulting
limited power in our study.
Unfortunately, there are no longitudinal studies assessing the development of DTI
parameters in patients with FRDA specifically. Also, since our study lacks a placebo group,
we consequently were not able to assess how diffusion parameters would have changed
without therapy.
Additional limitations of this study include using a DTI acquisition protocol with only six
directions of diffusion gradients, and the relatively small number of study participants.
CONCLUSION
In this exploratory study, TBSS revealed extensive WM changes in patients with FRDA
following therapy with rhuEPO. This finding supports the exciting potential of rhuEPO for
neuro-protection and –regeneration in humans. Additionally, our findings, in combination
with previously published results,16, 17 support the potential of diffusivity parameters to act
as valuable biomarkers in the assessment of disease progression and therapeutic response.
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Figure 1.
(A, B) Areas of significant increase in fractional anisotropy (FA, red-yellow) and axial
diffusivity (AD, blue) after therapy with recombinant human erythropoietin (rhuEPO) in
patients with Friedreich ataxia (FRDA). Significance threshold was set to p<0.05, family-
wise error corrected.
In the background, the TBSS skeleton is shown in green, superimposed on a T1 weighted
image. Images follow the radiological convention (right hemisphere is shown on the left).
Slices shown are at X = 12, Y = 10, Z = 37 in MNI space. (C) Absolute values of FA and
AD before and after rhuEPO therapy for each patient. For this graph, FA and AD
were averaged over all voxels that showed a significant longitudinal increase in the
respective diffusivity measure.
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